ReviewBiomaterials research2018
Theranostics and contrast agents for magnetic resonance imaging.
Review in Biomaterials research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 75 citations in OpenAlex.
- Beyond radiotheranostics: how imaging modality defines theranostics.European radiology experimental · 2026Review
- AI-driven nanomedicine for cancer theranostics.Molecular cancer · 2026Review
- Nanoparticles in the treatment of osteoporosis: recent advances in nanoparticles for the treatment of osteoporosis.RSC advances · 2025Review
- Current Trends and Advances in Nanoplatforms-Based Imaging for Cancer Diagnosis.Indian journal of microbiology · 2025Article
- Harnessing Biopolymer Gels for Theranostic Applications: Imaging Agent Integration and Real-Time Monitoring of Drug Delivery.Gels (Basel, Switzerland) · 2024Review
- Long-termNanoscale advances · 2024Article
- The advancing of polymeric core-shell ZnO nanocomposites containing 5-fluorouracil for improving anticancer activity in colorectal cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Green Dentistry in Oral Cancer Treatment Using Biosynthesis Superparamagnetic Iron Oxide Nanoparticles: A Systematic Review.Cancer management and research · 2024Review
- Contrasting Properties of Polymeric Nanocarriers for MRI-Guided Drug Delivery.Nanomaterials (Basel, Switzerland) · 2023Review
- Multifunctional Layered Double Hydroxides for Drug Delivery and Imaging.Nanomaterials (Basel, Switzerland) · 2023Review
- Design of A3B-Porphyrin Conjugates with Terpyridine as Potential Theranostic Agents: Synthesis, Complexation with Fe(III), Gd(III), and Photodynamic Activity.Pharmaceutics · 2023Article
- Advanced theragnostics for the central nervous system (CNS) and neurological disorders using functional inorganic nanomaterials.Advanced drug delivery reviews · 2023Review
- Exploring atherosclerosis imaging with contrast-enhanced MRI using PEGylated ultrasmall iron oxide nanoparticles.Frontiers in bioengineering and biotechnology · 2023Article
- Biocompatible carbonized iodine-doped dots for contrast-enhanced CT imaging.Biomaterials research · 2022Article
- Challenges and opportunities in the development of metal-based anticancer theranostic agents.Bioscience reports · 2022Review
- Craft of Co-encapsulation in Nanomedicine: A Struggle To Achieve Synergy through Reciprocity.ACS pharmacology & translational science · 2022Review
- Iron-doped calcium phytate nanoparticles as a bio-responsive contrast agent inScientific reports · 2022Article
- Protein-Based Nanoparticles for the Imaging and Treatment of Solid Tumors: The Case of Ferritin Nanocages, a Narrative Review.Pharmaceutics · 2021Review
- Mitochondria-targeted nanoparticles (mitoNANO): An emerging therapeutic shortcut for cancer.Biomaterials and biosystems · 2021Review
- Iron-Quercetin Complex Preconditioning of Human Peripheral Blood Mononuclear Cells Accelerates Angiogenic and Fibroblast Migration: Implications for Wound Healing.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMagnetic resonance imaging is one of the diagnostic tools that uses magnetic particles as contrast agents. It is noninvasive methodology which provides excellent spatial resolution. Although magnetic resonance imaging offers great temporal and spatial resolution and rapid in vivo images acquisition, it is less sensitive than other methodologies for small tissue lesions, molecular activity or cellular activities. Thus, there is a desire to develop contrast agents with higher efficiency. Contrast agents are known to shorten both T1 and T2. Gadolinium based contrast agents are examples of T1 agents and iron oxide contrast agents are examples of T2 agents. In order to develop high relaxivity agents, gadolinium or iron oxide-based contrast agents can be synthesized via conjugation with targeting ligands or functional moiety for specific interaction and achieve accumulation of contrast agents at disease sites. MAIN BODY: This review discusses the principles of magnetic resonance imaging and recent efforts focused on specificity of contrast agents on specific organs such as liver, blood, lymph nodes, atherosclerotic plaque, and tumor. Furthermore, we will discuss the combination of theranostic such as contrast agent and drug, contrast agent and thermal therapy, contrast agent and photodynamic therapy, and neutron capture therapy, which can provide for cancer diagnosis and therapeutics.
conclusionThese applications of magnetic resonance contrast agents demonstrate the usefulness of theranostic agents for diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.